P/E ratio for Sarepta Therapeutics (SRPT)

P/E ratio history for Sarepta Therapeutics from 2001 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Gilead Sciences GILD	19.2	-217.61%	🇺🇸 USA
Novavax NVAX	-1.76	-89.27%	🇺🇸 USA
Avidity Biosciences RNA	-14.8	-9.75%	🇺🇸 USA
BioCryst Pharmaceuticals BCRX	-6.54	-59.98%	🇺🇸 USA
Alnylam Pharmaceuticals ALNY	-67.2	310.96%	🇺🇸 USA
PTC Therapeutics PTCT	-4.21	-74.27%	🇺🇸 USA
Insmed INSM	-14.2	-13.11%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.